• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Long-term effectiveness of BAY e 5009-nitrendipine in the treatment of mild and moderate arterial hypertension.

作者信息

Esper R J, Esper R C, Baglivo H P, Castro J M, Rohwedder R W, Menna J

出版信息

J Cardiovasc Pharmacol. 1984;6 Suppl 7:S1096-9.

PMID:6085374
Abstract

Thirty-seven white patients of both sexes were studied to determine the efficacy and tolerance of nitrendipine for long ambulatory treatment in patients suffering from mild to moderate essential arterial hypertension whose response to the drug had been effective in a previous study. They all suffered from mild essential arterial hypertension, with diastolic arterial blood pressure (DBP) of 95-104 mm Hg, and moderate arterial hypertension with DBP of 105-114 mm Hg, in WHO Stage I or II, according to the clinical, radiological, electrocardiographic, and ophthalmoscopic examinations. In a previous study, all of them had been subjected to tensional controls, performed hourly during an 8-h period to assess their hypertension. Later, they were treated with increasing doses of nitrendipine, administered once or twice daily, until DBP figures under 90 mm Hg were obtained in at least five of the eight controls of each daily profile. All of them agreed to take part in the present research and underwent heart rate and arterial blood pressure controls in supine and standing position every 14 days during 24 periods. Simultaneous clinical and weight controls were performed. Moreover, an electrocardiogram was made every 28 days, and blood and urine tests were performed every 3 months. Of the 37 patients, 31 completed the 24 periods of 2 weeks each. Therefore, of 888 possible controls only 837 controls were made and submitted for assessment. Eighteen patients (48.6%) went on with the initial dose throughout the study or were able to reduce it. Eleven (29.7%) had to increase it, and in eight cases (21.6%) it was either increased or reduced.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
Long-term effectiveness of BAY e 5009-nitrendipine in the treatment of mild and moderate arterial hypertension.
J Cardiovasc Pharmacol. 1984;6 Suppl 7:S1096-9.
2
Comparison of nitrendipine combined with low-dose hydrochlorothiazide to hydrochlorothiazide alone in mild to moderate essential hypertension.尼群地平联合小剂量氢氯噻嗪与单用氢氯噻嗪治疗轻至中度原发性高血压的比较。
J Cardiovasc Pharmacol. 1984;6 Suppl 7:S1105-8.
3
The calcium channel blocker nitrendipine in single- and multiple-agent antihypertensive regimens: preliminary report of a multicenter study.钙通道阻滞剂尼群地平在单药及联合用药抗高血压治疗方案中的应用:一项多中心研究的初步报告
J Cardiovasc Pharmacol. 1984;6 Suppl 7:S1077-84.
4
Muzolimine and nitrendipine in the treatment of arterial hypertension.
Z Kardiol. 1985;74 Suppl 2:60-5.
5
Clinical experience with long-term nitrendipine treatment in essential hypertension.硝苯地平长期治疗原发性高血压的临床经验。
J Cardiovasc Pharmacol. 1984;6 Suppl 7:S1090-5.
6
Efficacy and safety of nitrendipine in patients with severe hypertension: a multiclinic study.尼群地平治疗重度高血压患者的疗效与安全性:一项多中心研究。
J Cardiovasc Pharmacol. 1984;6 Suppl 7:S1053-9.
7
Acute and long-term effects of nitrendipine on resting and exercise hemodynamics in essential hypertension.尼群地平对原发性高血压静息和运动血流动力学的急性及长期影响。
J Cardiovasc Pharmacol. 1984;6 Suppl 7:S1043-8.
8
Antihypertensive therapy with the long-acting calcium antagonist nitrendipine.使用长效钙拮抗剂尼群地平进行抗高血压治疗。
J Cardiovasc Pharmacol. 1984;6 Suppl 7:S1073-6.
9
Nitrendipine and atenolol: comparison and combination in the treatment of arterial hypertension.尼群地平和阿替洛尔:治疗动脉高血压的比较与联合应用
Arzneimittelforschung. 1985;35(4):727-9.
10
[Nitrendipine, a new calcium antagonist, in the therapy of arterial hypertension].尼群地平,一种新型钙拮抗剂,用于动脉高血压的治疗
Minerva Med. 1985 Nov 3;76(42):1983-90.

引用本文的文献

1
Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.尼群地平。对其药效学和药代动力学特性以及治疗高血压的疗效的综述。
Drugs. 1987 Feb;33(2):123-55. doi: 10.2165/00003495-198733020-00003.